|
|
Post by mannmade on Oct 17, 2016 21:01:18 GMT -5
As some of you may know, I have been speaking with a lot of doctors and people with diabetes regarding AFREZZA in an effort to volunteer my time to see MannKind succeed for a variety of my own personal reasons, that yes include the fact that I am an investor, although that is not my main motivation.
Today I spoke with an endo who specializes in diabetes and has one patient on it who mostly uses it for corrections. This doctor was formerly involved in the research of AFREZZA and said he had high hopes for it then. He is also formerly affiliated as a practicing doctor at a major US medical school facility endocrinology department and now has a solo practice. This doctor also believes in the benefits of ultra rapid acting insulins.
So when I asked him what he thought about AFREZZA he said he saw two benefits with it, the first being no needles which he said with needles now at 1/32 in size this was not really much of an issue for his patients. The second benefit was of course the fast in/fast out action. However, he qualified this by saying he knew there was a slight decline in lung function and was not sure of it's long term effects on the lungs even though he understood the lung function was supposed to return.
The other thing he was skeptical about was the lack of severe hypos and the reports of people lowering their Hba1c's into the mid 5's without such severe hypos. He also mentioned he would want to see a person's c-peptide count along with their Hba1c.
As a result of his concerns and skepticism he saw no reason to recommend AFREZZA to his patients.
To his credit he said he would meet with me to go through AFREZZA and the real world benefits being experienced by users currently. We are scheduled to meet in November.
My sense from this conversation and others is that the label is a big issue for many doctors. As well as a perceived potential lung safety issue.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 17, 2016 21:08:05 GMT -5
As some of you may know, I have been speaking with a lot of doctors and people with diabetes regarding AFREZZA in an effort to volunteer my time to see MannKind succeed for a variety of my own personal reasons, that yes include the fact that I am an investor, although that is not my main motivation. Today I spoke with an endo who specializes in diabetes and has one patient on it who mostly uses it for corrections. This doctor was formerly involved in the research of AFREZZA and said he had high hopes for it then. He is also formerly affiliated as a practicing doctor at a major US medical school facility endocrinology department and now has a solo practice. This doctor also believes in the benefits of ultra rapid acting insulins. So when I asked him what he thought about AFREZZA he said he saw two benefits with it, the first being no needles which he said with needles now at 1/32 in size this was not really much of an issue for his patients. The second benefit was of course the fast in/fast out action. However, he qualified this by saying he knew there was a slight decline in lung function and was not sure of it's long term effects on the lungs even though he understood the lung function was supposed to return. The other thing he was skeptical about was the lack of severe hypos and the reports of people lowering their Hba1c's into the mid 5's without such severe hypos. He also mentioned he would want to see a person's c-peptide count along with their Hba1c. As a result of his concerns and skepticism he saw no reason to recommend AFREZZA to his patients. To his credit he said he would meet with me to go through AFREZZA and the real world benefits being experienced by users currently. We are scheduled to meet in November. My sense from this conversation and others is that the label is a big issue for many doctors. As well as a perceived potential lung safety issue. did you let him know most of the hypo's in the study was for 1 patient .. so essentially Afrezza could reduce hypos? did you ask him how many of his patients are compliant in taking insulin due to needles? and the average A1c with time in range? |
|
|
|
Post by mannmade on Oct 17, 2016 21:16:17 GMT -5
Yes to the above but I also have be careful when speaking with medical professionals as I am not one. This is a process of discovery, then dialogue to see if I can provide enough useful info to have him consider that AFREZZA may be better thank he currently thinks.
|
|
|
|
Post by slugworth008 on Oct 17, 2016 21:16:40 GMT -5
As some of you may know, I have been speaking with a lot of doctors and people with diabetes regarding AFREZZA in an effort to volunteer my time to see MannKind succeed for a variety of my own personal reasons, that yes include the fact that I am an investor, although that is not my main motivation. Today I spoke with an endo who specializes in diabetes and has one patient on it who mostly uses it for corrections. This doctor was formerly involved in the research of AFREZZA and said he had high hopes for it then. He is also formerly affiliated as a practicing doctor at a major US medical school facility endocrinology department and now has a solo practice. This doctor also believes in the benefits of ultra rapid acting insulins. So when I asked him what he thought about AFREZZA he said he saw two benefits with it, the first being no needles which he said with needles now at 1/32 in size this was not really much of an issue for his patients. The second benefit was of course the fast in/fast out action. However, he qualified this by saying he knew there was a slight decline in lung function and was not sure of it's long term effects on the lungs even though he understood the lung function was supposed to return. The other thing he was skeptical about was the lack of severe hypos and the reports of people lowering their Hba1c's into the mid 5's without such severe hypos. He also mentioned he would want to see a person's c-peptide count along with their Hba1c. As a result of his concerns and skepticism he saw no reason to recommend AFREZZA to his patients. To his credit he said he would meet with me to go through AFREZZA and the real world benefits being experienced by users currently. We are scheduled to meet in November. My sense from this conversation and others is that the label is a big issue for many doctors. As well as a perceived potential lung safety issue. Your post highlights the need for marketing - to drive patient demand, which of course, has been mentioned on this board ad nauseum. |
|
|
|
Post by slugworth008 on Oct 17, 2016 21:17:24 GMT -5
As some of you may know, I have been speaking with a lot of doctors and people with diabetes regarding AFREZZA in an effort to volunteer my time to see MannKind succeed for a variety of my own personal reasons, that yes include the fact that I am an investor, although that is not my main motivation. Today I spoke with an endo who specializes in diabetes and has one patient on it who mostly uses it for corrections. This doctor was formerly involved in the research of AFREZZA and said he had high hopes for it then. He is also formerly affiliated as a practicing doctor at a major US medical school facility endocrinology department and now has a solo practice. This doctor also believes in the benefits of ultra rapid acting insulins. So when I asked him what he thought about AFREZZA he said he saw two benefits with it, the first being no needles which he said with needles now at 1/32 in size this was not really much of an issue for his patients. The second benefit was of course the fast in/fast out action. However, he qualified this by saying he knew there was a slight decline in lung function and was not sure of it's long term effects on the lungs even though he understood the lung function was supposed to return. The other thing he was skeptical about was the lack of severe hypos and the reports of people lowering their Hba1c's into the mid 5's without such severe hypos. He also mentioned he would want to see a person's c-peptide count along with their Hba1c. As a result of his concerns and skepticism he saw no reason to recommend AFREZZA to his patients. To his credit he said he would meet with me to go through AFREZZA and the real world benefits being experienced by users currently. We are scheduled to meet in November. My sense from this conversation and others is that the label is a big issue for many doctors. As well as a perceived potential lung safety issue. Kudos to you for your efforts. |
|
|
|
Post by mannmade on Oct 17, 2016 21:19:14 GMT -5
In my personal opinion it is a need for label change and an expanded FDA approved list of talking points. As I am not employed by mnkd I can say whatever I like for the most part so long as it is true and or positioned as my opinion.
Mnkd staff are limited in what the FDA will allow them to say to doctors and in their advertising messages.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 17, 2016 21:28:02 GMT -5
The label is a huge issue for Dr's. I have been told by a Dr from Mt Sinai in NYC as well as three other Endos outside NYC. The Dr from My Sinai said it was not worth the risk of his license. Welcome to the world we live in. Your Dr farts when he sits down with you and someone wants to sue for a million dollars
|
|
|
|
Post by agedhippie on Oct 17, 2016 21:29:34 GMT -5
As some of you may know, I have been speaking with a lot of doctors and people with diabetes regarding AFREZZA in an effort to volunteer my time to see MannKind succeed for a variety of my own personal reasons, that yes include the fact that I am an investor, although that is not my main motivation. Today I spoke with an endo who specializes in diabetes and has one patient on it who mostly uses it for corrections. This doctor was formerly involved in the research of AFREZZA and said he had high hopes for it then. He is also formerly affiliated as a practicing doctor at a major US medical school facility endocrinology department and now has a solo practice. This doctor also believes in the benefits of ultra rapid acting insulins. So when I asked him what he thought about AFREZZA he said he saw two benefits with it, the first being no needles which he said with needles now at 1/32 in size this was not really much of an issue for his patients. The second benefit was of course the fast in/fast out action. However, he qualified this by saying he knew there was a slight decline in lung function and was not sure of it's long term effects on the lungs even though he understood the lung function was supposed to return. The other thing he was skeptical about was the lack of severe hypos and the reports of people lowering their Hba1c's into the mid 5's without such severe hypos. He also mentioned he would want to see a person's c-peptide count along with their Hba1c. As a result of his concerns and skepticism he saw no reason to recommend AFREZZA to his patients. To his credit he said he would meet with me to go through AFREZZA and the real world benefits being experienced by users currently. We are scheduled to meet in November. My sense from this conversation and others is that the label is a big issue for many doctors. As well as a perceived potential lung safety issue. did you let him know most of the hypo's in the study was for 1 patient .. so essentially Afrezza could reduce hypos? did you ask him how many of his patients are compliant in taking insulin due to needles? and the average A1c with time in range? You are getting a couple of things confused here. The endo is not talking about the trials data when he is talking about hypos, he is talking about what he would expect to see from experience if you were getting an HbA1c below 6. He also answered your question on needle compliance, "with needles now at 1/32 in size this was not really much of an issue for his patients." (I think that should be 32g rather than 1/32). Needles are not a compliance issue, people need to get past that because it's not a selling point. The most interesting point he made was that he would want to see the c-peptide results as well as the HbA1c. Basically he suspects that some of the results are due to the person's own insulin mitigating the diabetes (around 15% of Type 1 diabetics make at least 10% of their normal insulin, late onset (LADA) have even better numbers). Other than that he sounds almost verbatim like my endo except mine is more concerned about the lung damage risk. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 17, 2016 21:37:22 GMT -5
did you let him know most of the hypo's in the study was for 1 patient .. so essentially Afrezza could reduce hypos? did you ask him how many of his patients are compliant in taking insulin due to needles? and the average A1c with time in range? You are getting a couple of things confused here. The endo is not talking about the trials data when he is talking about hypos, he is talking about what he would expect to see from experience if you were getting an HbA1c below 6. He also answered your question on needle compliance, "with needles now at 1/32 in size this was not really much of an issue for his patients." (I think that should be 32g rather than 1/32). Needles are not a compliance issue, people need to get past that because it's not a selling point. The most interesting point he made was that he would want to see the c-peptide results as well as the HbA1c. Basically he suspects that some of the results are due to the person's own insulin mitigating the diabetes (around 15% of Type 1 diabetics make at least 10% of their normal insulin, late onset (LADA) have even better numbers).Other than that he sounds almost verbatim like my endo except mine is more concerned about the lung damage risk. well in that case , that person's own insulin should also have been in action when they were using injectables? or did it turn on when they started on Afrezza? makes me wonder ummmmmm |
|
|
|
Post by brotherm1 on Oct 17, 2016 21:42:30 GMT -5
As some of you may know, I have been speaking with a lot of doctors and people with diabetes regarding AFREZZA in an effort to volunteer my time to see MannKind succeed for a variety of my own personal reasons, that yes include the fact that I am an investor, although that is not my main motivation. Today I spoke with an endo who specializes in diabetes and has one patient on it who mostly uses it for corrections. This doctor was formerly involved in the research of AFREZZA and said he had high hopes for it then. He is also formerly affiliated as a practicing doctor at a major US medical school facility endocrinology department and now has a solo practice. This doctor also believes in the benefits of ultra rapid acting insulins. So when I asked him what he thought about AFREZZA he said he saw two benefits with it, the first being no needles which he said with needles now at 1/32 in size this was not really much of an issue for his patients. The second benefit was of course the fast in/fast out action. However, he qualified this by saying he knew there was a slight decline in lung function and was not sure of it's long term effects on the lungs even though he understood the lung function was supposed to return. The other thing he was skeptical about was the lack of severe hypos and the reports of people lowering their Hba1c's into the mid 5's without such severe hypos. He also mentioned he would want to see a person's c-peptide count along with their Hba1c. As a result of his concerns and skepticism he saw no reason to recommend AFREZZA to his patients. To his credit he said he would meet with me to go through AFREZZA and the real world benefits being experienced by users currently. We are scheduled to meet in November. My sense from this conversation and others is that the label is a big issue for many doctors. As well as a perceived potential lung safety issue. How many doctors have you spoken with regarding affrezza Manmade? Over what time period? How many were pro Afrezza and how many were against it? Are the thoughts of this doctor you spoke with today indicative of the thoights of the other doctors you takked with? |
|
|
|
Post by cjc04 on Oct 17, 2016 21:46:11 GMT -5
He's been involved with Afrezza that long and still doesn't have these basic results?  My wife was up with low blood sugars 3 or 4 times a week with an A1c of 6.5..... so imagine what her highs were on a daily basis and the damage they were doing. NOW,,,, she never gets up in the middle of the night and has an A1c of 5.7..... how is this not common knowledge by now? |
|
|
|
Post by cjm18 on Oct 17, 2016 21:49:12 GMT -5
How depressing. This thread contradicts what mike said about the doctors way back in April. He said they were excited about afrezza.
|
|
|
|
Post by agedhippie on Oct 17, 2016 21:49:57 GMT -5
You are getting a couple of things confused here. The endo is not talking about the trials data when he is talking about hypos, he is talking about what he would expect to see from experience if you were getting an HbA1c below 6. He also answered your question on needle compliance, "with needles now at 1/32 in size this was not really much of an issue for his patients." (I think that should be 32g rather than 1/32). Needles are not a compliance issue, people need to get past that because it's not a selling point. The most interesting point he made was that he would want to see the c-peptide results as well as the HbA1c. Basically he suspects that some of the results are due to the person's own insulin mitigating the diabetes (around 15% of Type 1 diabetics make at least 10% of their normal insulin, late onset (LADA) have even better numbers).Other than that he sounds almost verbatim like my endo except mine is more concerned about the lung damage risk. well in that case , that person's own insulin should also have been in action when they were using injectables? or did it turn on when they started on Afrezza? makes me wonder ummmmmm Yes that would have helped with injected as well as with Afrezza. None the less it's why the endo is asking about c-peptide results, he wants to gauge if that is assisting. There is an effect where when you change treatments or drugs you may put in more effort or care and consequently get better results - it's why trials are usually blinded. This is also why anecdotal evidence gets dismissed by doctors. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 17, 2016 21:50:02 GMT -5
He's been involved with Afrezza that long and still doesn't have these basic results? My wife was up with low blood sugars 3 or 4 times a week with an A1c of 6.5..... so imagine what her highs were on a daily basis and the damage they were doing. NOW,,,, she never gets up in the middle of the night and has an A1c of 5.7..... how is this not common knowledge by now? Agreed. may be he is a slooooooooooooooooooooooooow learner. |
|
|
|
Post by sportsrancho on Oct 17, 2016 21:56:04 GMT -5
How depressing. This thread contradicts what mike said about the doctors way back in April. He said they were excited about afrezza. There are many that are excited:-). This one will be also when Mannmade gets done talking to him. |
|
